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Background: Experimental studies suggest that galectin-3 (Gal-3), a beta-galactosidase binding lectin, is an important mediator of cardiac 
fibrosis. Gal-3 predicts prognosis in patients with heart failure (HF). Whether elevated Gal-3 levels precede the development of HF is unknown.
Methods: Gal-3 levels were measured in 3,353 participants in the Framingham Heart Study offspring cohort (59 years, 53% women). The relation 
of Gal-3 to incident HF was assessed using Cox proportional hazards regression.
Results: Increasing Gal-3 quartiles were associated with risk of incident HF (Figure). Gal-3 was associated with incident HF in age- and sex-
adjusted (HR 1.28 per 1 SD increase in log-Gal-3, 95% CI 1.14-1.43, P<0.0001), and multivariable-adjusted analyses, accounting for age, sex, 
hypertension, body-mass index, diabetes mellitus, current smoking status, prevalent coronary heart disease, valvular heart disease, atrial fibrillation, 
and B-type natriuretic peptide (HR 1.23, 95% CI 1.04-1.47, P=0.02). Gal-3 was also associated with all-cause mortality (multivariable-adjusted HR 
1.15, 95% CI 1.04-1.28, P=0.008).
Conclusion: Our findings demonstrate that higher levels of Gal-3, a marker of cardiac fibrosis, are associated with an increased risk of new onset 
HF and all-cause mortality in the community. This suggests that cardiovascular injury due to fibrosis may be evident long before the clinical onset of 
HF. These findings may motivate future targeted therapies aimed at modulating the Gal-3 pathway.
 
